114 related articles for article (PubMed ID: 20806183)
1. Chromogranin A (CgA)--the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood.
Glinicki P; Jeske W
Endokrynol Pol; 2010; 61(4):384-7. PubMed ID: 20806183
[TBL] [Abstract][Full Text] [Related]
2. [Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].
Glinicki P; Jeske W
Endokrynol Pol; 2011; 62 Suppl 1():25-8. PubMed ID: 22125107
[TBL] [Abstract][Full Text] [Related]
3. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
Glinicki P; Jeske W
Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
[TBL] [Abstract][Full Text] [Related]
4. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
[TBL] [Abstract][Full Text] [Related]
5. [Current diagnostic procedure on neuroendocrine differentiation of prostate cancer].
Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
Urologia; 2011; 78(2):132-6. PubMed ID: 21574146
[TBL] [Abstract][Full Text] [Related]
6. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
7. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods.
Glinicki P; Kapuścińska R; Jeske W
Endokrynol Pol; 2010; 61(4):346-50. PubMed ID: 20806177
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
9. Comparison of chromogranin A (CgA) levels in serum and plasma (EDTA2K) and the respective reference ranges in healthy males.
Glinicki P; Jeske W; Kapuścińska R; Zgliczyński W
Endokrynol Pol; 2015; 66(1):53-6. PubMed ID: 25754282
[TBL] [Abstract][Full Text] [Related]
10. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract][Full Text] [Related]
11. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
12. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
14. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of preoperative chromogranin A expression in prostate cancer after radical prostatectomy.
Masieri L; Lanciotti M; Gontero P; Marchioro G; Mantella A; Zaramella S; Minervini A; Lapini A; Carini M; Serni S
Arch Ital Urol Androl; 2012 Mar; 84(1):17-21. PubMed ID: 22649955
[TBL] [Abstract][Full Text] [Related]
16. Correlation between age and Chromogranin A determination in prostate diseases.
Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M
Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of chromogranin A are not predictive of high-grade, poorly differentiated prostate cancer: results from an Italian biopsy cohort.
De Nunzio C; Albisinni S; Presicce F; Lombardo R; Cancrini F; Tubaro A
Urol Oncol; 2014 Feb; 32(2):80-4. PubMed ID: 23153859
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A (CgA) in adrenal tumours.
Glinicki P; Jeske W; Bednarek-Papierska L; Kasperlik-Załuska A; Rosłonowska E; Gietka-Czernel M; Zgliczyński W
Endokrynol Pol; 2013; 64(5):358-62. PubMed ID: 24186592
[TBL] [Abstract][Full Text] [Related]
20. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]